R&D Pipeline Overview
AmMax has established a robust pipeline targeting CSF1R. In addition to tenosynovial giant cell tumor wherein an
overexpression of CSF1 drives the pathogenesis, AmMax’s pipeline addresses a number of other diseases with critical unmet medical needs, such as idiopathic pulmonary fibrosis, retinal disease (nAMD/DME) and polycystic kidney diseases, by leveraging the action of AMB-05X on inflammation, fibrosis and neovascularization.
The technology basis for AmMax’s platform stems from the critical yet diverse roles played by the CSF1/CSF1R pathway. Via research collaboration with academic institutions, we continue to expand our pipeline to unlock the full potential of the CSF1R platform.